Therefore, they propose that the underlying antiarrhythmic mechanism of flecainide in CPVT attributes to its RyR2 blockade but not its intrinsic sodium channel inhibiting action. The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.